Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth
Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- ...
Inhibikase Therapeutics appoints Mark Iwicki as CEO
Inhibikase Therapeutics (IKT) appointed Mark Iwicki as the company’s CEO, replacing Milton Werner, founder of Inhibikase, effective February ...
Business Insider4d
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth
Werner, founder of Inhibikase, effective February 14, 2025. Additionally, effective February 14, 2025, Amit Munshi, a member of the Board of Directors of the Company (the “Board”) and veteran ...
Inhibikase Therapeutics: Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth
Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON, Feb.
Mena FN5d
Inhibikase Appoints Industry Veteran Mark Iwicki As CEO To Drive Next Stage Of Company’S Growth
BOSTON, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or“Company”), today announced the appointment of Mark Iwicki as the Company's Chief ...
ETF Daily News5d
What is HC Wainwright’s Estimate for IKT Q1 Earnings?
Inhibikase Therapeutics, Inc. (NYSE:IKT – Free Report) – Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for Inhibikase Therapeutics in a research report issued on ...